Defining and Measuring the Affordability of New Medicines: A Systematic Review
- 5 May 2017
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 35 (8) , 777-791
Abstract
Background In many healthcare systems, affordability concerns can lead to restrictions on the use of expensive efficacious therapies. However, there does not appear to be any consensus as to the terminology used to describe affordability, or the thresholds used to determine whether new drugs are affordable. Objectives The aim of this systematic review was to investigate how affordability is defined and measured in healthcare. Methods MEDLINE, EMBASE and EconLit databases (2005–July 2016) were searched using terms covering affordability and budget impact, combined with definitions, thresholds and restrictions, to identify articles describing a definition of affordability with respect to new medicines. Additional definitions were identified through citation searching, and through manual searches of European health technology assessment body websites. Results In total, 27 definitions were included in the review. Of these, five definitions described affordability in terms of the value of a product; seven considered affordability within the context of healthcare system budgets; and 15 addressed whether products are affordable in a given country based on economic factors. However, there was little in the literature to indicate that the price of medicines is considered alongside both their value to individual patients and their budget impact at a population level. Conclusions Current methods of assessing affordability in healthcare may be limited by their focus on budget impact. A more effective approach may involve a broader perspective than is currently described in the literature, to consider the long-term benefits of a therapy and cost savings elsewhere in the healthcare system, as well as cooperation between healthcare payers and the pharmaceutical industry to develop financing models that support sustainability as well as innovation.Keywords
Funding Information
- Novartis Pharma (Agora Think Tank)
This publication has 42 references indexed in Scilit:
- What is personalized medicine: sharpening a vague term based on a systematic literature reviewBMC Medical Ethics, 2013
- The High Cost of Cancer Drugs and What We Can Do About ItMayo Clinic Proceedings, 2012
- Mapping the availability, price, and affordability of antiepileptic drugs in 46 countriesEpilepsia, 2012
- Practical measurement of affordability: an application to medicinesBulletin of the World Health Organization, 2012
- Capacidade aquisitiva e disponibilidade de medicamentos para doenças crônicas no setor públicoRevista Panamericana de Salud Pública, 2012
- Pharmaceutical patents, R&D incentives and access to new drugs: new ways of progress at the crossroadThe European Journal of Health Economics, 2011
- Improving patient access to cancer drugs in India: Using economic modeling to estimate a more affordable drug cost based on measures of societal valueInternational Journal of Technology Assessment in Health Care, 2011
- Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countriesMedical Science Monitor, 2011
- Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysisThe Lancet, 2009
- Finanzierbarkeit steigender Gesundheitsausgaben in Deutschland: eine makroökonomische BetrachtungGesundheitsökonomie & Qualitätsmanagement, 2005